PMVP
PMV PHARMACEUTICALS, INC.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $0.00 | — | — |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $0.00 | $1.24 | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| D.E. Shaw | Q3 2024 | Q1 2026 | — | +0% |
| Millennium Management | Q3 2024 | Q4 2025 | — | +0% |
| AQR Capital Management | Q3 2024 | Q4 2024 | — | +0% |
| Viking Global Investors | Q4 2020 | Q3 2022 | → $17 | -47% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at PMV Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001644348-26-000003Jun 5, 2026
- Form 40001124164-26-000002Jun 5, 2026
- Form 40001329959-26-000002Jun 5, 2026
- Form 40001797209-26-000002Jun 5, 2026
- Form 40001579824-26-000003Jun 5, 2026
- Form 40002006668-26-000002Mar 9, 2026
- Form 40001613482-26-000002Mar 9, 2026
- Form 40001825192-26-000002Mar 9, 2026
- Form 40001341642-26-000002Mar 9, 2026
- Form 40001341642-25-000004Oct 29, 2025
- Form 40000947871-25-000927Oct 27, 2025
- Form 40000947871-25-000854Sep 12, 2025
- Form 40001415889-25-019386Jul 3, 2025
- Form 40001415889-25-019384Jul 3, 2025
- Form 40001415889-25-019382Jul 3, 2025
Fundamentals
XBRL · PMV PHARMACEUTICALS, INC.Annual figures sourced directly from PMV PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for PMV Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 5, 2026
- 10-QQuarterly reportMay 12, 2026
- 8-KMaterial eventMay 12, 2026
- DEF 14AProxy statementApr 22, 2026
- 8-KMaterial eventMar 6, 2026
- 10-KAnnual reportMar 6, 2026
- 10-QQuarterly reportNov 12, 2025
- 8-KMaterial eventNov 12, 2025
- 8-KMaterial eventSep 10, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
- 8-KMaterial eventJun 9, 2025
- 10-QQuarterly reportMay 9, 2025
- 8-KMaterial eventMay 9, 2025
- DEF 14AProxy statementApr 25, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | open | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | Q1 2026 | $0.00 | — | +0% |
| AQR Capital Management | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q4 2025 | $0.00 | — | +0% |
| Viking Global Investors | Q4 2020 | Q3 2022 | $32 | $17 | -47% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.